Research Article
Visualization and quantification of disease progression in multiple system atrophy
Article first published online: 7 JUL 2006
DOI: 10.1002/mds.21032
Copyright © 2006 Movement Disorder Society
Additional Information
How to Cite
Hauser, T.-K., Luft, A., Skalej, M., Nägele, T., Kircher, T. T.J., Leube, D. T. and Schulz, J. B. (2006), Visualization and quantification of disease progression in multiple system atrophy. Mov. Disord., 21: 1674–1681. doi: 10.1002/mds.21032
Publication History
- Issue published online: 20 OCT 2006
- Article first published online: 7 JUL 2006
- Manuscript Accepted: 5 MAR 2006
- Manuscript Revised: 22 FEB 2006
- Manuscript Received: 26 DEC 2005
Funded by
- DFG Research Center
- Abstract
- Article
- References
- Cited By
Keywords:
- multiple system atrophy;
- ataxia;
- neurodegenerative disorders;
- parkinsonian syndromes;
- MR imaging;
- voxel-based morphometry
Abstract
To visualize and quantify disease progression in multiple system atrophy (MSA) from cerebellar type (MSA-C), we combined two magnetic resonance imaging (MRI) techniques, voxel-based morphometry (VBM) and 3D-based volumetry. Patients suffering from MSA-C (n = 14) were imaged twice with an interval of 2.0 ± 0.2 years. We first applied VBM to map brain morphology changes between MSA patients and controls and to identify brain areas that showed a significant amount of atrophy. Using 3D-based volumetry, we confirmed that in MSA-C patients, the brainstem including medulla and pons, vermis and cerebellar hemispheres, caudate nucleus and putamen showed significant atrophy compared with controls. Next, we used 3D-based volumetry to analyze the atrophy rates. Atrophy rates in patients with MSA were significantly different from controls for putamen (−11.4% ± 2.6%/year), vermis (−12.3% ± 2.9%/year), and cerebellar hemispheres (−6.6% ± 1.1%/year). The results show that 3D-based MRI volumetry is a tool that allows the disease progression of MSA to be followed over a time period of 2 years and suggest that it may serve as a surrogate marker in clinical trials to measure disease progression. © 2006 Movement Disorder Society

1531-8257/asset/MDS_left.gif?v=1&s=a99f3b698e6ae32e96dbc75c912d289e5c35649d)
1531-8257/asset/MDS_right.gif?v=1&s=4d3c8316b533aa4e41b7101a2d6fa6f082cf2505)
1531-8257/asset/cover.gif?v=1&s=cbca75ec4eec6abb5c8560896c83f19bae8de2b1)